A61K31/34

17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure

Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C.sub.1-C.sub.4) linear or branched alkyl or guanidine or guanidino (C.sub.1-C.sub.4) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C═C; the thick line represents a bond in the β configuration; the wavy line represents a bond both in the α and β configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.

17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure

Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C.sub.1-C.sub.4) linear or branched alkyl or guanidine or guanidino (C.sub.1-C.sub.4) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C═C; the thick line represents a bond in the β configuration; the wavy line represents a bond both in the α and β configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.

Methods and Compositions for the Treatment of Multiple Sclerosis
20220142967 · 2022-05-12 ·

Compositions and methods based on isosorbide esters for the treatment of multiple sclerosis.

Methods and Compositions for the Treatment of Multiple Sclerosis
20220142967 · 2022-05-12 ·

Compositions and methods based on isosorbide esters for the treatment of multiple sclerosis.

Metabolically stable 5-HMF derivatives for the treatment of hypoxia

5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.

Metabolically stable 5-HMF derivatives for the treatment of hypoxia

5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.

Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases
11312725 · 2022-04-26 · ·

Novel isohexide esters and isohexide compositions are prepared and used in improving skin health and condition.

Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases
11312725 · 2022-04-26 · ·

Novel isohexide esters and isohexide compositions are prepared and used in improving skin health and condition.

Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases
11312725 · 2022-04-26 · ·

Novel isohexide esters and isohexide compositions are prepared and used in improving skin health and condition.

HEPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:


X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.